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ABSTRACT
Ataxia telangiectasia mutated (ATM), a PI-3 kinase
essential for maintaining genomic stability, has
been shown to regulate TRF1, a negative mediator
of telomerase-dependent telomere extension.
However, little is known about ATM-mediated
TRF1 phosphorylation site(s) in vivo. Here, we
report that ATM phosphorylates S367 of TRF1 and
that this phosphorylation renders TRF1 free of chro-
matin. We show that phosphorylated (pS367)TRF1
forms distinct non-telomeric subnuclear foci and
that these foci occur predominantly in S and G2
phases, implying that their formation is cell cycle
regulated. We show that phosphorylated
(pS367)TRF1-containing foci are sensitive to prote-
asome inhibition. We find that a phosphomimic
mutation of S367D abrogates TRF1 binding to telo-
meric DNA and renders TRF1 susceptible to protein
degradation. In addition, we demonstrate that
overexpressed TRF1-S367D accumulates in the
subnuclear domains containing phosphorylated
(pS367)TRF1 and that these subnuclear domains
overlap with nuclear proteasome centers. Taken
together, these results suggest that phosphorylated
(pS367)TRF1-containing foci may represent nuclear
sites for TRF1 proteolysis. Furthermore, we show
that TRF1 carrying the S367D mutation is unable to
inhibit telomerase-dependent telomere lengthening
or to suppress the formation of telomere doublets
and telomere loss in TRF1-depleted cells, suggest-
ing that S367 phosphorylation by ATM is important
for the regulation of telomere length and stability.
INTRODUCTION
Telomeres are specialized heterochromatic structures
found at the ends of linear eukaryotic chromosomes.
Mammalian telomeric DNA consists of TTAGGG
tandem repeats that are coated with shelterin, a
telomere-speciﬁc protein complex composed of TRF1,
TRF2, TIN2, Rap1, TPP1 and POT1 (1–3). The shelterin
complex functions not only to protect telomeres from
being recognized as double strand breaks (1,4) but
also to maintain telomere length homeostasis, which is
intimately associated with tumorigenesis and aging.
Disruption of shelterin proteins has been shown to
induce the de-protection of telomeres, resulting in
telomere abnormalities including telomere end-to-end
fusions, telomere loss and telomere doublets/fragile telo-
meres (more than one telomeric signal at a single chroma-
tid end) (4–12). These dysfunctional telomeres are
recognized as damaged DNA (8–10,12,13) and can con-
tribute to genomic instability.
TRF1, a component of the shelterin complex, binds
speciﬁcally to duplex telomeric DNA (14), and is
implicated in telomere replication, telomere protection
and telomere length maintenance. Deletion of TRF1
promotes the formation of fragile telomeres in S phase,
a phenomena thought to be associated with replication-
dependent defects (6,9). It has been suggested that TRF1
is required to prevent fork stalling, allowing efﬁcient
replication of telomeric DNA (9). Loss of TRF1 from
telomeres has been shown to induce telomerase-dependent
telomere lengthening whereas overexpression of TRF1
results in telomere shortening, suggesting that TRF1 nega-
tively regulates telomerase-dependent telomere extension,
perhaps by restricting the access of telomerase to the ends
of telomeres (15–17).
TRF1 interacts with ataxia telangiectasia mutated
(ATM) (18), a PI-3 kinase essential for maintaining
genomic stability. Mutations in ATM give rise to ataxia–
telangiectasia (AT), an autosomal recessive disorder
characterized by immunodeﬁciency, spontaneous chromo-
somal instability, hypersensitivity to ionizing irradiation
and a predisposition to cancer (19). Primary ﬁbroblasts
derived from AT patients accumulate telomere
abnormalities and show an elevated rate of telomere short-
ening as compared to cells from normal individuals (20–
25). In agreement with these ﬁndings, inhibition of ATM
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telomerase-expressing cancer cells, indicative of the role
of ATM as a positive mediator of telomere length main-
tenance (26). It has been suggested that ATM promotes
telomerase-dependent telomere elongation by negatively
regulating TRF1 association with telomeric DNA (26).
However, little is known about the ATM phosphorylation
site(s) of TRF1 important for telomere length
maintenance.
In this report, we demonstrate that ATM phosphoryl-
ates S367 of TRF1 both in vivo and in vitro. We show
that a phosphomimic mutation of S367D abrogates
TRF1 interaction with telomeric DNA. Using a
phosphospeciﬁc antibody, we demonstrate that
phosphorylated (pS367)TRF1 forms distinct subnuclear
foci that are not associated with telomeric DNA. These
results reveal that the phosphorylation of S367 by ATM
prevents TRF1 binding to telomeric DNA. We show that
phosphorylated (pS367)TRF1-containing foci predomin-
antly occur in S and G2 phases, implying that the forma-
tion of these foci is cell cycle regulated. In addition, we
ﬁnd that phosphorylated (pS367)TRF1-containing foci
are sensitive to proteasome inhibition. We show that the
phosphomimic mutation of S367D renders mutant TRF1
susceptible to protein degradation and promotes its
localization in phosphorylated (pS367)TRF1-containing
subnuclear domains, which overlap with nuclear prote-
asome centers. These results suggest that phosphorylated
(pS367)TRF1-containing foci may represent nuclear pro-
teolytic sites for TRF1 degradation. Furthermore, we
demonstrate that the phosphomimic mutation of S367D
impairs the ability of TRF1 not only to inhibit telomerase-
dependent telomere elongation but also to suppress the
formation of telomere doublets and telomere loss in
TRF1-depleted cells, suggesting that S367 phosphoryl-
ation by ATM plays an important role in regulating
telomere length and stability.
MATERIALS AND METHODS
DNA constructs, cell culture and retroviral infection
The oligonucleotides encoding siRNAs directed against
TRF1 have been previously described (12). The annealed
oligonucleotides were ligated into pRetroSuper (pRS)
vector (kindly provided by Titia de Lange, Rockefeller
University), giving rise to pRetroSuper-shTRF1. The
QuickChange site-directed mutagenesis kit (Strategene)
was used to create TRF1 mutations of S367A and
S367D as well as silent mutations resistant to shTRF1 as
previously described (12). Wild-type TRF1 and TRF1
mutants (S367A and S367D) carrying silent mutations re-
sistant to shTRF1 were then subcloned into either the
retroviral vector pWZL-N-Myc (27) or the bacterial ex-
pression vector pHis-Parallel-2 (28).
Cells were grown in DMEM medium with 10% fetal
bovine serum (FBS) for GM09607 (Coriell), GM05849
(Coriell), GM16666 (Coriell), GM16667 (Coriell),
HeLaI.2.11, HeLaII, GM847, Phoenix cells and 15%
FBS for IMR90 cells, supplemented with non-essential
amino acids, glutamine, 100 U/ml penicillin and
0.1mg/ml streptomycin. The ATM-deﬁcient AT22IJE
cell line was transfected with either an ATM expression
construct or an empty vector, giving rise to
ATM-corrected (GM16667) and ATM-deﬁcient
(GM16666) stable cell lines, respectively (29). HeLaI.2.11
and HeLaII are two sublines of HeLa cells of different
telomere length (4,30). Retroviral gene delivery was
carried out as described (31–33) to generate stable cell
lines. HeLaII cells expressing pRS/pWZL, shTRF1/
pWZL, shTRF1/TRF1, shTRF1/S367A or shTRF1/
S367Dweremaintainedintheselectionmediumcontaining
either puromycin (2mg/ml) or hygromycin (90mg/ml)
alternatingevery2weeksfortheentiretyoftheexperiments.
Cell cycle analysis
Synchronization of HeLaI.2.11 with a double thymidine
block was carried out essentially as described (34) with the
exception that 2mM thymidine instead of aphidicolin was
used. For FACS analysis, two million cells were ﬁxed in
80% ethanol, digested with RNase A (2mg/ml), stained
with 50mg/ml propidium iodide, and analyzed using a
Becton–Dickinson LSRII located at the SickKids-UHN
ﬂow cytometry facility, Toronto, ON, Canada.
Protein extracts, differential salt extraction of chromatin
and immunoblotting
Differential salt extraction of chromatin was performed as
described (35). Protein extracts and immunoblotting were
carried out essentially as described (27,34). Rabbit poly-
clonal anti-pS367 antibody was developed by Biosynthesis
Inc. against a TRF1 peptide containing phosphorylated
serine 367 (VSK-pS-QPVTPEKHRARKR). Antibodies
used were anti-TRF1 (a kind gift from Titia de Lange),
anti-proteasome (PA1-1962, Pierce), anti-Myc (9E10,
Calbiochem), anti-H3K9m3 (Upstate) and anti-g-tubulin
(GTU88, Sigma).
Production of recombinant TRF1 proteins
Production of 6xHis-tagged TRF1 proteins was carried
out as described (10,12). Brieﬂy, induction of wild-type
and mutant TRF1 proteins was carried out overnight
with 0.1mM Isopropyl b-D-1-thiogalactopyranoside at
room temperature. The cell pellet was resuspended in
binding buffer [20 mM Tris–HCl (pH 7.9) and 500mM
NaCl] and then lysed by sonication. Following centrifuga-
tion, the supernatant was incubated with nickel-resin
(Qiagen) for 2h at 4 C. The beads were washed three
times with 60mM imidazole and bound proteins were
eluted with a buffer containing 1 M imidazole, 20mM
Tris–HCl (pH 7.9) and 0.5 M NaCl.
Immunoprecipitation of ATM and in vitro kinase assays
Immunoprecipitation of ATM was performed as previous-
ly described (26). Brieﬂy, cell lysates were made in lysis
buffer [50 mM Tris–HCl (pH 7.5), 150mM NaCl, 10%
Glycerol, 1% Tween-20, 50mM NaF, 1mM NaVO4,
0.1mM DTT, 0.5mM PMSF, 0.5mg/ml leupeptin],
followed by sonication (50% duty cycle, nine pulses and
output of three). For each ATM IP, 4mg anti-ATM (Ab-3)
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were used. Following 1h incubation on ice, 25ml protein
G sepharose slurry (GE Healthcare) was added to each IP
and continued incubation for 1h at 4 C. The IP pellet was
washed twice in lysis buffer, once in LiCl buffer (0.5 M
LiCl and 0.1 M Tris–HCl (pH 7.5)], and twice in kinase
buffer [(10mM Hepes pH 7.9, 50mM NaCl, 10mM
MgCl2, 10mM MnCl2,5mM ATP and 1mM DTT). For
ATM kinase assays, the ﬁnal IP pellet was resuspended
in kinase buffer, mixed with bacterial-derived recombin-
ant wild-type TRF1 (2mg) or TRF1-S367A (2mg) in
the presence of 10mCi g-
32P-ATP in a ﬁnal volume of
15ml. For ATM kinase assays followed by in vitro
gel-shift assays, cold ATP (1.8mM) was used. For
DNA-PKcs kinase assays, recombinant wild-type TRF1
(2mg) or TRF1-S367A (2mg) was incubated with 20
units of puriﬁed DNA-PKcs (Promega, V5811) in the
presence of g-
32P-ATP according to the manufacturer’s
instruction.
Immunoﬂuorescence and ﬂuorescence in situ hybridization
Immunoﬂuoresence (IF) was performed essentially as
described (10,32,34). IF–FISH (ﬂuorescence in situ hybrid-
ization) analysis was conducted as described (9). Brieﬂy,
cells grown on coverslips were ﬁxed at RT for 10min in
PBS-buffered 2% paraformaldehyde, washed in PBS twice
for 5min each, followed by incubation at RT for 30min in
blocking buffer containing 1mg/ml BSA, 3% goat serum,
0.1% Triton X-100 and 1mM EDTA in PBS. Blocked
coverslips were incubated with anti-pS367 antibody in
blocking buffer at RT for 1h. After three washes in
PBS, coverslips were incubated with ﬂuorescein
isothiocyanate (FITC)-conjugated donkey anti-rabbit
(1:100, Jackson Laboratories) at RT for 30min.
Subsequently, cells on coverslips were ﬁxed again in
PBS-buffered 2% paraformaldehyde for 5min and
followed by dehydration in a series of 70, 85 and 100%
ethanol. The air-dried coverslips were denatured at 80 C
for 10min and hybridized with 0.5mg/ml tetramethyl
rhodamine isothiocyanate (TRITC)-conjugated-(TTAGG
G)3 peptide nucleic acid (PNA) probe (Biosynthesis Inc.)
for 2h in the dark at RT. Following incubation, cover slips
were washed with 70% formamide and 10mM Tris–HCl
(pH 7.2) twice for 15min. After three washes in PBS, DNA
was counter-stained with 4,6-diamidino-2-phenylindole
(DAPI; 0.2mg/ml) and embedded in 90% glycerol/10%
PBS containing 1mg/ml p-phenylene diamine (Sigma).
All cell images were recorded on a Zeiss Axioplan 2 micro-
scope with a Hammamatsu C4742-95 camera and pro-
cessed in Open Lab.
Metaphase chromosome spreads
Metaphase chromosome spreads were essentially prepared
as described (4,32). TRF1-depleted HeLaII cells express-
ing various TRF1 alleles or the vector alone were arrested
in nocodazole (0.1mg/ml) for 90min. Following arrest,
cells were harvested by trypsinization, incubated for
7min at 37 C in 75mM KCl, and ﬁxed in freshly made
methanol/glacial acidic acid (3:1). Cells were stored
overnight at 4 C, dropped onto slides and air-dried over-
night in a chemical hood.
FISH analysis on metaphase chromosome spreads was
carried out essentially as described (32,36). Slides with
chromosome spreads were incubated with 0.5mg/ml
FITC-conjugated-(CCCTAA)3 PNA probe (Biosynthesis
Inc.) for 2h at room temperature. Following incubation,
slides were washed, counter-stained with 0.2mg/ml DAPI
and embedded in 90% glycerol/10% PBS containing
1mg/ml p-phenylene diamine (Sigma). All cell images
were recorded on a Zeiss Axioplan 2 microscope with
a Hammamatsu C4742-95 camera and processed in
Open Lab.
In vitro gel-shift assays
In vitro gel-shift assays were done essentially as described
(26,37) with an end-labeled 188-bp BglII–XhoI fragment
from plasmid pTH12 (37). Bacteria-derived recombinant
wild-type or mutant TRF1 protein was incubated with the
end-labeled DNA (1ng) at room temperature for 20min in
a2 0 - ml reaction containing 20mM HEPES–KOH
(pH7.9), 150mM KCl, 5% (v/v) glycerol, 4% (w/v)
Ficoll, 1mM EDTA, 0.1mM MgCl2, 0.5mM DTT,
70mg BSA, 2mg sheared Escherichia coli DNA and 50ng
b-casein. The DNA–protein complexes were fractionated
on a 0.7% agarose gel run in 0.1 TBE (8.9mM
Tris-base, 8.9mM boric acid, 0.2mM EDTA) at 130V
for 1h at room temperature. Gels were dried and
exposed to PhosphorImager screens.
Telomere length analysis
Genomic DNA isolated from cells was digested with RsaI
and HinfI and loaded onto a 0.7% agarose gel in 0.5 
TBE. Blotting for telomeric fragments was carried out
according to standard protocols (15). The average telo-
meric restriction fragment length was determined by
PhosphorImager analysis using ImageQuant and MS
Excel as described (38).
RESULTS
ATM phosphorylates S367 of TRF1 both in vivo
and in vitro
Phosphorylation has been shown to play an important role
in modulating the function of TRF1 in telomere metabol-
ism (12,26,39–41). In an effort to identify TRF1 phosphor-
ylation sites in vivo, we generated an HT1080 cell line
stably expressing Flag-tagged TRF1. Mass spectrometry
analysis of immunoprecipitated Flag-TRF1 indicated
serine at position 367 of TRF1 to be a candidate phos-
phorylation site in vivo (Figure 1A and data not shown).
To further investigate the phosphorylation of S367 of
TRF1 in vivo, we raised an antibody against a TRF1
peptide containing phosphorylated S367, referred to as
anti-pS367. Anti-pS367 antibody speciﬁcally recognized
the phosphorylated TRF1 peptide but not the unphos-
phorylated TRF1 peptide (Figure 1B). The ability of
anti-pS367 to speciﬁcally recognize the phosphorylated
(pS367)TRF1 peptide was further demonstrated by
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modiﬁed peptide had no effect on binding of anti-pS367
antibody to the phosphorylated peptide, pre-incubation of
the phosphorylated peptide completely abrogated its
ability to bind the phosphorylated peptide (Figure 1C).
We showed that anti-pS367 antibody predominantly
recognized a protein band with an apparent molecular
weight indistinguishable from that of endogenous TRF1
in HeLa cell lysate (Figure 1D). Depletion of TRF1
resulted in a loss of TRF1 recognized by anti-pS367
antibody in vivo (Figure 1E). Taken together, these
results suggest that anti-pS367 antibody speciﬁcally recog-
nizes phosphorylated S367 of TRF1 in vivo.
S367 (S
367Q) of TRF1 matches the consensus sequence
for ATM and we decided to investigate whether ATM
may be involved in phosphorylating S367 of TRF1. To
Figure 1. ATM phosphorylates S367 of TRF1 both in vivo and in vitro.( A) Schematic diagram of TRF1 domain structures. S367 of TRF1 in red
was identiﬁed by mass spectrometry analysis to be a candidate phosphorylation site. (B) Afﬁnity-puriﬁed anti-pS367 antibody speciﬁcally recognizes
TRF1 peptide containing phosphorylated S367 (pS367-peptide). An increasing amount of peptide either carrying unmodiﬁed S367 (S367-peptide) or
phosphorylated S367 (pS367-peptide) was spotted on a nitrocellulose membrane, followed by immunoblotting with afﬁnity-puriﬁed anti-pS367
antibody or crude serum. The amount of peptide spotted from left to right is 0.7, 1.75 and 3.5mg. (C) Peptide competition assays.
Afﬁnity-puriﬁed anti-pS367 antibody was incubated with 5.5mg of either unmodiﬁed (S367-peptide) or phosphorylated peptide (pS367-peptide)
prior to immunoblotting. Crude serum was used to show the presence of pS367-peptide on the nitrocellulose membrane. The amount of
pS367-peptide spotted from left to right is 0.7, 1.75 and 3.5mg. (D) Western analysis of phosphorylated TRF1. The whole cell extract (20mg)
from HeLaII cells was immunoblotted with afﬁnity-puriﬁed anti-pS367 antibody. (E) Depletion of endogenous TRF1 leads to loss of phosphorylated
TRF1 recognized by anti-pS367 antibody. HeLaII cells were infected with retrovirus expressing shTRF1 or the vector pRS alone. Western analysis
was performed with anti-pS367 or anti-TRF1 antibody. The g-tubulin blot was used as a loading control. (F) In vitro kinase assays.
Bacterial-expressed his-tagged wild-type TRF1 (2mg) or TRF1 mutant S367A (2mg) was incubated with either ATM immunoprecipitated from
HeLa cells or puriﬁed DNA-PKcs in the presence of g-
32P-ATP. (G) ATM inhibition leads to a diminished anti-pS367 staining. HeLaI.2.11 cells were
treated with DMSO, KU55933 (an ATM inhibitor) or NU7026 (a DNA-PKcs inhibitor) for 90min, followed by western analysis. Immunoblotting
was performed with anti-pS367, anti-TRF1 or anti-g-tubulin antibody. (H) Loss of anti-pS367 staining in ATM-deﬁcient cells. Western analysis of
cell extracts from IMR90 cells, HeLaI.2.11 cells and ATM-deﬁcient cells (GM09607 and GM05849). Immunoblotting was performed with anti-pS367
or anti-g-tubulin antibody. (I) NU7026 leads to a further reduction in S367 phosphorylation in ATM-deﬁcient cells. GM09607 cells were treated with
DMSO, KU55933 or NU7026 for 90min, following by immunoblotting with anti-pS367 or anti-g-tubulin antibody.
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assays with bacterial-derived recombinant wild-type
TRF1 or mutant TRF1 carrying a single amino acid sub-
stitution at S367 (TRF1-S367A). We found that while
ATM immunoprecipitated from HeLa cells was able to
phosphorylate wild-type TRF1, consistent with previous
ﬁndings (18,26), the alanine substitution of S367 impaired
TRF1 phosphorylation by ATM in vitro (Figure 1F).
However, the S367A mutation had no effect on TRF1
phosphorylation by DNA-PKcs in vitro (Figure 1F), indi-
cative of the speciﬁcity of S367 phosphorylation by ATM.
Using the phospho-speciﬁc anti-pS367 antibody, we
examined the effect of ATM inhibition on S367 phosphor-
ylation in vivo. HeLa cells were treated with either
dimethyl sulfoxide (DMSO), KU55933, a highly speciﬁc
inhibitor of ATM (42) or NU7026, a speciﬁc inhibitor of
DNA-PKcs (43). We found that treatment with KU55933
but not NU7026 led to a reduction in S367 phosphoryl-
ation (Figure 1G). Furthermore, we detected a substantial
reduction in S367 phosphorylation in ATM-deﬁcient
GM09607 and GM05849 cells compared to
ATM-proﬁcient IMR90 and HeLaI.2.11 cells (Figure
1H). Treatment of GM09607 cells with the DNA-PKcs
inhibitor NU7026 led to a further decrease in S367 phos-
phorylation and such decrease was not observed in
KU55933-treated GM09607 cells (Figure 1I), implying
that DNA-PKcs may phosphorylate S367 in vivo in the
absence of functional ATM. Taken together, these
results demonstrate that ATM phosphorylates S367 of
TRF1 both in vitro and in vivo.
Phosphorylated (pS367)TRF1 forms distinct non-telomeric
nuclear foci that are cell cycle regulated
We have shown that TRF1 is phosphorylated at S367
in vivo and we decided to examine the nuclear localization
of phosphorylated (pS367)TRF1. Using the phospho-
speciﬁc anti-pS367 antibody, we performed indirect IF
on both primary and transformed cell lines. We found
that in interphase cells, anti-pS367 staining formed
distinct nuclear foci in both primary and transformed
cell lines (Figure 2A) and that these foci were very heter-
ogenous in size, a feature distinct from telomere staining.
We found that depletion of TRF1 led to a severe reduction
in anti-pS367 staining and the formation of anti-pS367-
containing foci (Figure 2B). On the other hand,
anti-pS367-containing foci were fully restored in
TRF1-depleted cells expressing wild-type TRF1 but not
in TRF1-depleted cells expressing TRF1 carrying either
a non-phosphorylatable mutation (S367A) or a phos-
phomimic mutation (S367D) (Figure 2B), suggesting that
these foci represent phosphorylated (pS367)TRF1. The
lack of rescue of anti-pS367-containing foci by TRF1
mutants demonstrates that phospho-speciﬁc anti-pS367
antibody does not recognize TRF1 carrying a single
amino acid substitution of S367. Phosphorylated
(pS367)TRF1-containing foci were also visible in early
prophase cells (Figure 2C); however, anti-pS367 staining
became very diffuse in the rest of mitosis from metaphase
to telophase (Figure 2C). These results suggest that the
formation of phosphorylated (pS367)TRF1-containing
foci may be cell cycle regulated.
To further investigate the nature of phosphorylated
(pS367)TRF1-containing foci, we conducted IF–FISH
analysis with anti-pS367 antibody in conjunction with a
TRITC-conjugated telomeric DNA-containing PNA
probe. We observed very little overlap between the
majority of bright foci stained by anti-pS367 and telo-
meric DNA (Figure 2D). Occasionally, we observed an
overlap between one or two bright anti-pS367 foci and
telomeric DNA (Figure 2D). While the nature of this
overlap is unknown, it may be insigniﬁcant due to the
high number of anti-pS367 foci (Figure 2D). Analysis of
a differential salt extraction of chromatin revealed that
while TRF1 was predominantly found in the chromatin-
bound fraction (420mM KCl), consistent with previous
ﬁndings (35), phosphorylated (pS367)TRF1 was over-
whelmingly associated with the chromatin-free fraction
(150mM KCl) (Figure 2E). Taken together, these results
demonstrate that phosphorylated (pS367)TRF1 is not
associated with telomere chromatin. We estimated that
1–5% of endogenous TRF1 may be phosphorylated at
S367 (Figure 2E).
To address the cell cycle-dependent nature of anti-pS367
staining, we arrested HeLaI.2.11 and GM847 cells at the
G1/S boundary with a double thymidine block and then
released them into fresh media for 0, 2, 4, 6, 8, 10 or 16h.
Consistent with our previous ﬁndings (34), we found that
HeLa cells progressed through S phase 2–6h post release
and enter mitosis 10h post release (Figure 3A). Analysis of
immunoﬂuoresence showed that the bright foci stained by
anti-pS367 antibody were predominantly seen in cells ﬁxed
2–8h post release from a double thymidine block whereas
very few cells arrested at G1/S or in G1 (16h post release
from a double thymidine block) displayed such foci
(Figure 3B and C). These results suggest that
phosphorylated (pS367)TRF1-containing foci are cell
cycle regulated, occuring in S and G2 phase.
ATM is required for the subnuclear localization of
phosphorylated (pS367)TRF1
To investigate whether phosphorylated (pS367)TRF1-
containing foci might be ATM-dependent, indirect IF
with anti-pS367 antibody was performed on HeLaI.2.11
cells treated with either DMSO or KU55933. We observed
a severe loss of anti-pS367 staining along with the dis-
appearance of distinct nuclear foci of phosphorylated
(pS367)TRF1 in KU55933-treated cells as compared to
DMSO-treated cells (Figure 4A). Treatment with
KU55933 led to a 6-fold reduction in the percentage of
cells exhibiting phosphorylated (pS367)TRF1-containing
foci (Figure 4B). The absence of distinct anti-pS367
nuclear foci was also evident in ATM-deﬁcient
GM09607 and GM05849 cells when compared to
ATM-proﬁcient IMR90 cells (Figure 4C and 4D). In
addition, we found that introduction of ATM into
ATM-deﬁcient cells restored phosphorylated
(pS367)TRF1-containing foci (Figure 4E and F). Taken
together, these results suggest that the subnuclear
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upon functional ATM.
The phosphomimic mutation S367D abrogates TRF1
association with telomeres and renders it susceptible to
degradation
We have shown that phosphorylation of S367 by ATM
renders TRF1 free of telomere chromatin in vivo.
Therefore we decided to investigate whether prephos-
phorylation of TRF1 by ATM might affect TRF1
binding to telomeric DNA in vitro. Bacteria-derived re-
combinant wild-type TRF1 was pre-incubated with
ATM either in the presence or absence of cold ATP
prior to gel-shift assays. We found that pre-incubation
of TRF1 with ATM in the presence of cold ATP
completely abrogated TRF1 binding to telomeric DNA
(Figure 5A), consistent with our previous ﬁndings that
ATM negatively regulates TRF1 binding to telomeric
DNA (26).
To further investigate the role of S367 phosphorylation
in TRF1 binding and stability, we changed S367 of TRF1
to either alanine (S367A, non-phosphorylatable) or
aspartic acid (S367D, phosphomimic). Using bacterial-
derived recombinant wild-type TRF1, TRF1-S367A and
TRF1-S367D, we performed in vitro gel-shift assays and
found that while TRF1-S367A bound telomeric DNA at a
level indistinguishable from wild-type TRF1, TRF1-
S367D displayed a severe defect in its interaction with
telomeric DNA (Figure 5B). To gain evidence that the
phosphomimic mutation of S367D might also affect
TRF1 association with telomeres in vivo,w e
Figure 2. Phosphorylated (pS367)TRF1 forms distinct nuclear foci that are not associated with telomere chromatin. (A) Indirect IF using anti-pS367
antibody was performed on human primary IMR90 cells as well as transformed HeLaI.2.11 and GM847 cells. Cell nuclei were stained with DAPI
shown in blue. (B) Indirect IF using anti-pS367 antibody was performed on TRF1-depleted HeLaII cells expressing the vector alone, wild-type
TRF1, TRF1-S367A or TRF1-S367D. Wild-type TRF1, TRF1-S367A or TRF1-S367D were engineered to be resistant to shTRF1. Cell nuclei were
stained with DAPI shown in blue. (C) Phosphorylated (pS367)TRF1-containing foci are visible in early prophase but become diffuse in the rest of
mitosis. Indirect IF using anti-pS367 antibody was performed on GM847 cells. Cell nuclei were stained with DAPI shown in blue. (D)
Phosphorylated (pS367)TRF1 is not associated with telomeric DNA. IF–FISH analysis was performed on ﬁxed GM847 cells with anti-pS367
antibody (green) in conjunction with TRITC-conjugated telomeric DNA-containing PNA probe (red). Cell nuclei were stained with DAPI shown
in blue. (E) Phosphorylated (pS367)TRF1 is predominantly free of chromatin. Differential salt (KCl) extraction of chromatin was performed on
HeLaI.2.11 cells. Immunoblotting was carried out with anti-pS367, anti-TRF1 or anti-H3K9m3 antibody. The anti-H3K9m3 blot was used as
control to assess the extraction of chromatin.
3980 Nucleic Acids Research, 2012,Vol.40, No. 9performed differential salt extraction of chromatin on
TRF1-depleted HeLaII cells stably expressing
Myc-TRF1, Myc-TRF1-S367A or Myc-TRF1-S367D.
We found that the majority of overexpressed Myc-TRF1
or Myc-TRF1-S367A was associated with chromatin
whereas very little of overexpressed Myc-TRF1-S367D
was associated with chromatin (Figure 5C), consistent
with our earlier ﬁnding that phosphorylated
(pS367)TRF1 is not associated with chromatin (Figure
2E). Expression of Myc-TRF1-S367D was comparable
to that of Myc-TRF1 or Myc-TRF1-S367A (Figure 5D),
suggesting that it is unlikely that the lack of Myc-TRF1-
T367D association with chromatin might have arisen from
a difference in protein expression. These results support
the notion that S367 phosphorylation by ATM prevents
TRF1 association with telomeric DNA.
To investigate whether S367 phosphorylation might be
involved in regulating TRF1 stability, we used
Figure 3. Phosphorylated (pS367)TRF1 forms distinct non-telomeric foci in a cell cycle regulated manner, enriched in S and G2 phases. (A) FACS
analysis of synchronized HeLaI.2.11 cells. y-axis, cell numbers; x-axis, relative DNA content on the basis of staining with propidium iodine. Asyn,
asynchronous population; 0–10h, cells were released for 0–10h from a double thymidine block. (B) Indirect IF using anti-pS367 antibody was
performed on GM847 cells released for 0–16h from a double thymidine block. Cell nuclei were stained with DAPI shown in blue. (C) Quantiﬁcation
of percentage of GM847 and HeLaI.2.11 cells exhibiting ﬁve or more phosphorylated (pS367)TRF1-containing foci. For each of the indicated
time-points post-release from a double thymidine block, a total of at least 1500 cells from three independent experiments were scored in blind for
both GM847 and HeLaI.2.11 cells. Standard deviations from three independent experiments are indicated.
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depleted HeLaII cells stably expressing various TRF1
alleles. We found that Myc-TRF1-S367D was less stable
than Myc-TRF1 or Myc-TRF1-T367A (Figure 5E). At
8h post-cycloheximide chase,  50% of Myc-TRF1-
S367D was degraded whereas <30% of degradation
was observed for Myc-TRF1-T367A or Myc-TRF1
(Figure 5F). Myc-TRF1-S367D was also observed to be
Figure 4. ATM is required for the subnuclear localization of phosphorylated (pS367)TRF1. (A) ATM inhibition leads to loss of phosphorylated
(pS367)TRF1-containing foci. Indirect IF was performed with anti-pS367 antibody on HeLaI.2.11 cells treated with either DMSO or KU55933. Cell
nuclei were stained with DAPI in blue. (B) Quantiﬁcation of DMSO-treated or KU55933-treated HeLaI.2.11 cells showing ﬁve or more
phosphorylated (pS367)TRF1-containing foci. A total of at least 1500 cells from three independent experiments were scored in blind for both
DMSO-treated and KU55933-treated cells. Standard deviations from three independent experiments are indicated. (C) ATM-deﬁcient cells lack
phosphorylated (pS367)TRF1-containing foci. IF was performed with anti-pS367 antibody on IMR90 cells as well as ATM-deﬁcient GM09607 and
GM05849 cells. Cell nuclei were stained with DAPI in blue. (D) Quantiﬁcation of ATM-proﬁcient or ATM-deﬁcient cells showing ﬁve or more
phosphorylated (pS367)TRF1-containing foci. A total of at least 1500 cells from three independent experiments were scored in blind for IMR90,
GM09607 and GM05849 cells. Standard deviations from three independent experiments are indicated. (E) Introduction of ATM into ATM-deﬁcient
cells restores phosphorylated (pS367)TRF1-containing foci. IF was conducted with anti-pS367 antibody on ATM-deﬁcient cells expressing either the
vector alone (GM16666) or complemented with ATM (GM16667). Cell nuclei were stained with DAPI in blue. (F) Quantiﬁcation of GM16666 or
GM16667 cells showing ﬁve or more phosphorylated (pS367)TRF1-containing foci. A total of 1500 cells from three independent experiments were
scored. Standard deviations from three independent experiments are indicated.
3982 Nucleic Acids Research, 2012,Vol.40, No. 9Figure 5. A phosphomimic mutation of S367D not only impairs the ability of TRF1 to interact with telomeric DNA but also renders it susceptible
to degradation. (A) Prephosphorylation of TRF1 by ATM abrogates its ability to bind telomeric DNA. Bacterial-derived recombinant TRF1 of
varying amouts as indicated above the lanes was pre-incubated with ATM immunoprecipiated from HeLa cells in the presence or absence of cold
ATP, followed by in vitro gel-shift assays. (B) TRF1-S367D is defective in binding to telomeric DNA. Bacterial-derived recombinant TRF1 proteins
were used in the gel-shift assays as indicated above the lanes. The positions of three TRF1-containing complexes (I, II and III) are indicated on the
right. The concentrations of recombinant TRF1 used were indicated above the lanes. (C) Differential salt (KCl) extraction of chromatin was
performed on TRF1-depleted HeLaII cells expressing Myc-tagged wild-type TRF1, Myc-tagged TRF1-S367A or Myc-tagged TRF1-T367D.
Immunoblotting was carried out with anti-Myc antibody. (D) Western analysis of expression of various Myc-tagged TRF1 proteins in
TRF1-depleted HeLaII cells. Immunoblotting was carried out with anti-Myc or anti-g-tubulin antibody. (E) Cycloheximide chase experiments.
TRF1-depleted HeLaII cells stably expressing Myc-TRF1, Myc-TRF1-S367A or Myc-TRF1-S367D were treated with 100mg/ml cycloheximide
for the indicated times, followed by immunoblotting of the lysates with anti-Myc or anti-g-tubulin antibody. (F) Quantiﬁcation of Myc-tagged
wild-type TRF1 (blue bars), Myc-tagged TRF1-S367A (burgundy bars) and Myc-tagged TRF1-S367D (light yellow bars) from (E). The signals from
the western blots were quantiﬁed with densitometry. The level of Myc-tagged TRF1 proteins is represented in arbitrary units after their signals were
normalized relative to those of g-tubulin. Standard deviations from three independent experiments are indicated. (G) Quantiﬁcation of cycloheximide
chase experiments from HT1080 cells stably expressing Myc-tagged wild-type (blue bars), Myc-tagged TRF1-S367A (burgundy bars) and Myc-tagged
TRF1-S367D (light yellow bars). Quantiﬁcation was conducted as described in 5F. Standard deviations from three independent experiments are
indicated.
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overexpressed in HT1080 cells (Figure 5G). These results
suggest that S367 phosphorylation by ATM renders TRF1
susceptible to protein degradation.
The subnuclear localization of phosphorylated
(pS367)TRF1 is sensitive to proteasome inhibition
Analysis of dual indirect IF with anti-pS367 antibody in
conjunction with anti-Myc antibody revealed that when
transiently expressed in HeLa cells, both Myc-TRF1 and
Myc-TRF1-S367A exhibited punctate nuclear staining
(Figure 6A), indicative of their association with telomeric
DNA (Figure 6A). While overexpressed Myc-TRF1 or
Myc-TRF1-S367A did not exhibit any overlap with en-
dogenous phosphorylated (pS367)TRF1 (Figure 6A),
overexpressed Myc-TRF1-S367D was found to co-localize
with phosphorylated (pS367)TRF1 (Figure 6A). Earlier
we have shown that a very small amount (1–5%) of
TRF1 is phosphorylated at S367 (Figure 2E) and therefore
it is likely that the vast majority of overexpressed
Myc-TRF1 is not phosphorylated at S367, which may
account for the apparent lack of an overlap between
anti-Myc and anti-pS367 staining in Myc-TRF1-
overexpressing HeLaII cells. In addition, we observed an
overlap between Myc-TRF1-S367D-containing foci and
proteasome-containing nuclear centers (Figure 6B), sug-
gesting that Myc-TRF1-S367D-containing foci are part
of nuclear proteasome centers. Consistent with this
notion, we found that treatment of cells with MG132, a
potent proteasome inhibitor, completely abrogated the
formation of phosphorylated (pS367)TRF1-containing
foci (Figure 6C). Taken together, these results suggest
that phosphorylated (pS367)TRF1-containing foci may
represent the nuclear proteolytic sites for TRF1
degradation.
TRF1 carrying a phosphomimic mutation of S367D is
unable to inhibit telomerase-dependent telomere
lengthening
To investigate the role of S367 phosphorylation in
telomere maintenance, we infected TRF1-depleted
HeLaII cells with retrovirus expressing the vector pWZL
alone, Myc-tagged wild-type TRF1, Myc-tagged TRF1-
S367A or Myc-tagged TRF1-S367D, giving rise to four
stable cell lines (shTRF1/pWZL, shTRF1/TRF1,
shTRF1/S367A, shTRF1/S367D). These stable cell lines
contained pools of cells and they were not single cell
clones. As a control, we also generated a HeLaII cell
line stably expressing two vectors pRetroSuper (pRS)
and pWZL. Myc-tagged wild-type TRF1, Myc-tagged
TRF1-S367A and Myc-tagged TRF1-S367D were resist-
ant to shTRF1 due to engineered silent mutations. We
chose to use TRF1-depleted cells for analysis of TRF1
mutants to minimize the interference from endogenous
TRF1.
HeLaII cells stably expressing pRS/pWZL, shTRF1/
pWZL, shTRF1/TRF1, shTRF1/S367A, shTRF1/S367D
were cultured for over 66 population doublings (PDs).
Depletion of TRF1 resulted in telomere elongation
(Figure 7A and B). Introduction of shTRF1-resistant
wild-type TRF1 into TRF1-depleted HeLaII cells
fully reversed shTRF1-mediated telomere lengthening
(Figure 7A–C). We found that TRF1-S367A was able to
reverse shTRF1-mediated telomere lengthening in
a manner similar to wild-type TRF1 (Figure 7A–C).
In contrast, a severe defect in suppressing shTRF1-
mediated telomere lengthening was reproducibly
observed in TRF1-depleted cells overexpressing TRF1-
S367D (Figure 7A–C). This defect was unlikely due to
the lack of protein expression (Figure 7D). TRF1-
S367D-expressing cells grew at a rate indistinguishable
from TRF1-S367A-expressing cells (Figure 7E), arguing
against the possibility that the difference in cell prolifer-
ation may account for the inability of TRF1-S367D to
inhibit telomere length maintenance. These results alto-
gether suggest that S367 phosphorylation negatively
regulates the ability of TRF1 to modulate telomerase-
dependent telomere lengthening.
TRF1 carrying a phosphomimic mutation of S367D fails
to suppress shTRF1-induced telomere doublets and
telomere loss
TRF1 has been shown to be important for telomere rep-
lication (6,9), the defect of which can give rise to fragile
telomeres (6,9), also known as telomere doublets.
Previously we have shown that depletion of TRF1
induces the formation of telomere doublets and telomere
loss, both of which can be suppressed by wild-type TRF1
(12). We asked whether S367 phosphorylation might
affect the ability of TRF1 to suppress these abnormalities.
FISH analysis was performed on metaphase cells derived
from HeLaII cells stably expressing shTRF1/pWZL,
shTRF1/TRF1, shTRF1/S367A or shTRF1/S367D.
Consistent with previous ﬁndings (12), we found that
overexpression of wild-type TRF1 was able to suppress
the formation of both telomere doublets and telomere
loss in TRF1-depleted cells (Figure 8A–C). Introduction
of TRF1-S367A into TRF1-depleted cells was also able to
suppress these telomere abnormalities (Figure 8A–C). On
the other hand, we found that overexpression of TRF1-
S367D failed to result in any reduction in telomere
doublets or telomere loss in TRF1-depleted HeLaII cells
(Figure 8B and C). In fact, we detected a further increase
in the formation of telomere doublets as a result of
TRF1-S367D expression in TRF1-depleted HeLaII cells
(Figure 8B). Aphidicolin, an inhibitor of DNA replica-
tion, has been shown to induce telomere doublets (6,9).
We observed a substantial increase in telomere doublets in
TRF1-depleted cells upon treatment with aphidicolin
(Figure 8D), consistent with a previous report that
the effect of aphidicolin was additive with the loss of
TRF1 (9). Such a increase was also observed in TRF1-
S367D-expressing cells (Figure 8D). Taken together, these
results suggest that the phosphomimic mutation of S367D
impairs TRF1 function in telomere replication.
DISCUSSION
In this report, we have demonstrated that ATM phos-
phorylates S367 of TRF1 both in vivo and in vitro.
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extraction and mutational analysis, we have shown that
the phosphorylation of S367 by ATM prevents TRF1 as-
sociation with telomere chromatin, consistent with
previous ﬁndings that ATM acts as a negative mediator
of TRF1 binding to telomeric DNA (26). These results
suggest that S367 may be a major phosphorylation site
for ATM to control TRF1 interaction with telomeric
DNA in vivo.
Previous work suggests that TRF1 undergoes phos-
phorylation at S219 by ATM in response to ionizing ir-
radiation (18). We did not observe any increase in the level
Figure 6. (A) Nuclear localization of overexpressed various Myc-tagged TRF1 proteins. Dual indirect IF with anti-pS367 in conjunction with
anti-Myc antibody was performed on HeLa cells transiently overexpressing Myc-TRF1, Myc-TRF1-S367A or Myc-TRF1-S367D. Cell nuclei
were stained with DAPI shown in blue. (B) Overexpressed TRF1-S367D colocalizes with nuclear proteasomes. Dual IF was conducted on
HeLaII cells transiently expressing Myc-S367D with anti-Myc antibody (red) in conjunction with either rabbit anti-proteasome (anti-PT)
antibody (green) or no primary antibody (no 1  Ab). Cell nuclei were stained with DAPI shown in blue. (C) Phosphorylated
(pS367)TRF1-containing foci are sensitive to proteasome inhibition. GM847 cells were treated with either DMSO or MG132 (12.5mM) for 4hr
prior to IF analysis with anti-pS367 antibody. Cell nuclei were stained with DAPI shown in blue.
Nucleic Acids Research,2012, Vol.40, No. 9 3985Figure 7. TRF1 carrying a phosphomimic mutation is defective in the inhibition of telomerase-dependent telomere lengthening. (A) Genomic blots
of telomeric restriction fragments from TRF1-depleted HeLaII cells (shTRF1) expressing either the vector alone (pWZL) or various TRF1 alleles as
indicated above the lanes. HeLaII cells expressing both pRS and pWZL were used as a control. PD are indicated above the lanes whereas DNA
molecular weight markers are shown on both left and right of the blots. About 3mg of RsaI/HinfI-digested genomic DNA from each sample was
used for gel electrophoresis. (B) Average telomere length of indicated cell lines was plotted against PD. (C) Average telomere length of indicated cell
lines was plotted against PD from a repeated experiment. (D) Western analysis of expression of various Myc-tagged TRF1 proteins in early and late
PDs. Immunoblotting was performed with anti-Myc antibody. The anti-g-tubulin blots were used as a loading control. (E) Growth curve of HeLaII
cells expressing various constructs as indicated. The number of PDs was plotted against days in culture.
3986 Nucleic Acids Research, 2012,Vol.40, No. 9of S367 phosphorylation in response to ionizing irradi-
ation, nor any association of S367 phosphorylation with
sites of DNA damage (M. McKerlie and X.-D. Zhu, un-
published data). These ﬁndings altogether suggest that
ATM may regulate TRF1 function through phosphoryl-
ation at distinctive sites.
Using a phospho-speciﬁc antibody, we have shown
that phosphorylated (pS367)TRF1 forms proteasome-
dependent subnuclear foci. Our ﬁnding that TRF1
carrying the phosphomimic mutation of S367D accumu-
lates in these foci and overlaps with nuclear proteasome
centers suggests that these foci may represent the nuclear
proteolytic sites for TRF1 degradation. Our ﬁndings are
consistent with previous studies that several nuclear
proteins are found to be detectable at proteasome-
associated nuclear foci while being degraded including
histones, splicing factor SC35, splicesomal components
(U1-70k, SmB/B0) and promyelocytic leukemia protein
Figure 8. Overexpression of TRF1-S367D promotes the formation of telomere doublets in TRF1-depleted HeLaII cells. (A) Images of metaphase
chromosomes depicting telomere abnormalities. Metaphase chromosomes were stained with DAPI and false-colored in red. Telomeric DNA was
detected by FISH using a FITC-conjugated (CCCTAA)3-containing PNA probe in green. Open arrows represent telomere doublets whereas asterisks
indicate telomere loss. (B) Quantiﬁcation of telomere doublets from TRF1-depleted cells expressing indicated constructs. For each cell line, a total of
3150–3750 chromosomes from 60 to 69 metaphase cells were scored in a blind manner for the presence of telomere doublets in B and D and telomere
loss in C. Standard deviations derived from three independent experiments are indicated. (C) Quantiﬁcation of telomere loss from TRF1-depleted
cells expressing indicated constructs. Telomere loss refers to chromatids without a detectable telomere signal. The total number of chromatid ends
without a detectable telomere signal was divided by the total number of chromatid ends scored, giving rise to the percentage of telomere loss per
chromatid end. (D) Quantiﬁcation of telomere doublets from aphidicolin-treated cells. TRF1-depleted cells expressing indicated constructs were
treated with aphidicolin (0.2mM) for 16h prior to FISH analysis.
Nucleic Acids Research,2012, Vol.40, No. 9 3987(PML) (44). Further studies are required to investigate the
kinetics of TRF1 turnover in these centers.
Proteasomes areknown to localize in both the cytoplasm
and the nucleus (45). It has been reported that
proteasome-mediated nuclear proteolysis takes place in
distinct nucleoplasmic foci that can partially overlap with
subnuclear structures such as PML and nuclear speckles
(46). However, we observed little overlap between
phosphorylated (pS367)TRF1-containing foci and PML
bodies, nuclear speckles or Cajal bodies (M. McKerlie
and X.-D. Zhu, unpublished data), suggesting that these
foci may represent a novel type of subnuclear domain.
Phosphorylation plays an important role in regulating
TRF1 interaction with telomeric DNA (12,26,39–41).
Previously we have shown that TRF1 is phosphorylated
on T371 by Cdk1 during mitosis and this phosphorylation
plays an important role in the resolution of sister chroma-
tids (12). S367 is located four amino acids upstream from
T371 in the linker region immediately preceding the DNA
binding domain (Myb domain) of TRF1 (Figure 1A).
The fact that S367 phosphorylation prevents TRF1 from
binding to telomeric DNA, along with our previous
ﬁnding that phosphorylation of T371 also keeps TRF1
away from telomere chromatin (12) suggest that phos-
phorylation in this portion of the linker region may inter-
fere with TRF1 binding to telomeric DNA, perhaps due to
the creation of unfavorable electrostatic interactions. We
have shown that S367 phosphorylation by ATM targets
TRF1 to proteasome-dependent nuclear foci, which is
associated with its increased susceptibility to protein deg-
radation. This contrasts with Cdk1-mediated T371 phos-
phorylation, which has been shown to increase the half-life
of TRF1 (12). Perhaps the temporal separation of these
two phosphorylation events (at different stages of the cell
cycle) may account for the differential role that these two
closely positioned sites play at telomeres. These results
highlight the tight regulation of TRF1 function and the
important role of post-translational modiﬁcations in this
control.
We have shown that phosphorylated (pS367)TRF1-
containing foci are cell cycle regulated, appearing predom-
inantly in S and G2 phases. ATM has been shown to be
associated with human telomeres in a cell cycle regulated
manner, peaking in S and G2 phases (47,48). Perhaps
when ATM is recruited to telomeres in S and G2 phase,
it phosphorylates TRF1 at S367, promoting its dissoci-
ation from telomeric DNA and its accumulation in
proteasome-dependent subnuclear domains. However,
we did not observe any signiﬁcant change in the level of
S367 phosphorylation throughout the cell cycle (data not
shown), raising the possibility that phosphorylation of
S367 by ATM per se may not be cell cycle regulated.
How phosphorylated (pS367)TRF1-containing foci are
predominantly formed in S and G2 phases requires
further investigation.
We have shown that TRF1 carrying the phosphomimic
mutation of S367D (TRF1-S367D) fails to suppress the
formation of telomere doublets and telomere loss in
TRF1-depleted cells. While telomere doublets are
thought to arise from a defect in telomere replication
(6,9), telomere loss can arise from homologous
recombination-mediated events (8). Our ﬁndings suggest
that S367 phosphorylation might play a role in
modulating the pathway(s) responsible for the formation
of telomere doublets or telomere loss.
TRF1 is required for efﬁcient telomere replication (6,9);
however, it needs to be removed from telomeres to
support telomerase-dependent telomere extension (15–
17,26). We have shown that TRF1-S367D is not only
defective in supporting telomere replication but also
unable to inhibit telomerase-dependent telomere exten-
sion. We have estimated that 1–5% of endogenous
TRF1 is phosphorylated at S367 in a cell cycle-dependent
manner. These results raise the possibility that the action
of ATM on S367 of TRF1 may occur only at a few telo-
meres, which might have a severe replication defect and
require the repair from telomerase. Taken together, these
results suggest that S367 phosphorylation by ATM is im-
portant for the regulation of telomere length and stability.
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